We are a multinational pharmaceutical group dedicated to improving the health and wellbeing of people in the markets we serve through the development, manufacture and marketing of a broad range of solid, liquid and injectable generic and in-licensed pharmaceutical products.
- 01-Mar-2010
- » Hikma will release its 2009 preliminary results on Wednesday, March 17, 2010
- LONDON, 1 March 2010 – Hikma Pharmaceuticals PLC (“Hikma”) (LSE: HIK) (Nasdaq Dubai: HIK), the fast growing multinational pharmaceutical Group, will release its 2009 preliminary results on Wednesday, 17 March 2010. The company will host a presentation for analysts at 9 am and a live webcast of the presentation will be available on Hikma’s website. www.hikma.com
- 11-Jan-2010
- » Hikma announces partnership with BioCryst for its pandemic flu product
- London, 11 January 2009: Hikma Pharmaceuticals PLC (“Hikma”) (LSE:HIK) (NASDAQ Dubai: HIK), a leading speciality pharmaceutical company, announces that it has signed an exclusive agreement to represent BioCryst in respect of its anti-viral product peramivir for pandemic flu treatment stockpiling opportunities with governments in the Middle East and North Africa (‘MENA’) region.
